Free Light Chain Testing in Diagnosis and Monitoring of Multiple Myeloma by N-Latex FLC Kappa and Lambda Assays

Wednesday, August 7, 3:30 – 4:30 p.m.
Exhibit Hall, Theater 1
Supported by Siemens Healthineers

Overview

Free light chain (FLC) kappa and lambda testing was incorporated in the diagnostic criteria for multiple myeloma requiring therapy by the International Myeloma Working Group in 2014. The test is also used to monitor response and relapse in light chain multiple myeloma (LCMM) and is frequently applied as an additional marker in multiple myeloma (MM) monitoring, together with serum and urine electrophoresis, immunofixation, and quantification of the M-protein. Data collected in a multicentric study comparing the N Latex FLC kappa and lambda method versus the FREELITE kappa and lambda method for diagnosis and monitoring of multiple myeloma patients and a comparison of both FLC methods versus clinical status will be presented.

Outcomes

Attendees will learn to:

  • Describe the FLC kappa and lambda testing application for diagnosis and monitoring of multiple myeloma.
  • Appraise the performance of N Latex FLC kappa and lambda assays compared to competitor methods.
  • Review the clinical performance of N Latex FLC kappa and lambda assays for diagnosis and monitoring of multiple myeloma.

Moderator

Dr. Claus Prümper
Senior Marketing Director
Siemens Healthineers
Frankfurt, Germany

Speaker

Maria Alice V. Willrich, PhD
Assistant Professor of Laboratory Medicine and Pathology - Mayo Clinic College of Medicine and Science
Consultant
Division of Clinical Biochemistry & Immunology, Department of Laboratory Medicine and Pathology
Mayo Clinic
Rochester, MN